Citigroup
MGRX icon

Citigroup’s Mangoceuticals MGRX Stock Holding History

Citigroup’s Portfolio MGRX Stock Details MGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1
Closed -$1 – 6212
2025
Q4 		$1 Buy
+1
New +$2 ﹤0.01% 5977

Other funds holding MGRX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
ACA
Ackerman Capital Advisors Dallas, Texas $488M AUM 14.36% 1-Year Est. Return
SG
StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return

Citigroup's MGRX Position: Q1 2026 in Review

Citigroup sold out of Mangoceuticals (MGRX) in Q1 2026, closing a stake of 1 share — an estimated $1 sold.

Citigroup first reported a position in MGRX in Q4 2025 and held it in 1 quarter. The position peaked at $1 in Q4 2025. 18 funds tracked by Wall St. Rank hold MGRX as of Q1 2026.

  • Citigroup reported no remaining Mangoceuticals position as of Q1 2026 after selling out during the quarter.
  • Citigroup sold 1 Mangoceuticals share in Q1 2026, an estimated $1.
  • Citigroup first reported a position in Mangoceuticals in Q4 2025 and held it in 1 quarter.
  • Citigroup's Mangoceuticals position peaked at $1 in Q4 2025.
  • 18 funds tracked by Wall St. Rank held Mangoceuticals as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.